This website is optimized for visualization with Firefox and Internet Explorer (8 or 9)

CLINICAL DEVELOPMENT PIPELINE

Regulatory Review

Phase 3

Phase 2

  • BTK inhibitor
    immunology
    LY3337641 (BTK inhibitor) is a new chemical entity that inhibits the Bruton's tyrosine kinase. LY3337641 is being studied for the treatment of rheumatoid arthritis.

    For more information on LY3337641 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • Mirikizumab
    LY3074828 (formerly known as IL-23 antibody) is a biologic entity that blocks the activity of the cytokine interleukin 23. LY3074828 is being studied for the treatment of immune diseases including ulcerative colitis and psoriasis.

    For more information on LY3074828 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • Dual Amylin Calcitonin Receptor Agonist
    DACRA-042 is a new biologic entity that acts as a dual agonist of both the amylin receptor and calcitonin receptor and is being studied for the treatment of diabetes.

    For more information on DACRA-042 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • GIP/GLP-1 Co-agonist Peptide
    LY3298176 (GIP/GLP-1 Co-agonist Peptide) is a new biologic entity that acts as a coagonist for both the gastric inhibitory polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor and is being studied for the treatment of diabetes.

    For more information on LY3298176 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • Ultra Rapid Insulin
    LY900014 (LY) is a novel formulation containing locally-acting excipients to accelerate insulin lispro absorption. LY900014 is a biologic entity being studied for the treatment of type 1 and type 2 diabetes

    For more information on LY900014 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • BACE inhibitor Alzheimer's
    LY3202626 (BACE Inhibitor), a chemical entity, is an oral beta secretase cleaving enzyme (BACE) inhibitor. LY3202626 is being studied for the treatment of Alzheimer's disease.

    For more information on LY3202626 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • Merestinib cancer (mer es’ ti nib)
    LY2801653 (formerly known as c-Met inhibitor) is a chemical entity that has been shown in vitro to be a reversible type II ATP-competitive inhibitor of MET, a receptor for hepatocyte growth factor. Preclinical testing also has shown LY2801653 to inhibit several other receptor tyrosine oncokinases including MST1R, FLT3, AXL, MERTK, TEK, ROS1, and DDR1/2 and the serine/threonine kinases MKNK1/2. LY2801653 is being studied for the treatment of cancer.

    For more information on LY2801653 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • PI3 Kinase/mTOR Dual Inhibitor
    LY3023414 (PI3 Kinase/mTOR dual Inhibitor) is a chemical entity being studied for development in combinations for the treatment of cancer.

    For more information on LY3023414 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • Prexasertib (prex” a ser’ tib)
    LY2606368 monomesylate monohydrate (formerly known as Chk1 inhibitor) is a chemical entity that preferentially binds to and inhibits checkpoint kinase 1 (Chk1), a global regulator of the mammalian cell cycle and, to a lesser extent, inhibits Chk2. LY2606368 monomesylate monohydrate is being studied for the treatment of cancer.

    For more information on LY2606368 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • Baricitinib
    atopic dermatitis
    LY3009104 (baricitinib, formerly known as JAK1/JAK2 Inhibitor) is a chemical entity that inhibits the activity of the Janus (JAK) 1 and 2 enzymes. LY3009104 is being studied for the treatment of atopic dermatitis.

    For more information on LY3009104 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • Baricitinib
    systemic lupus erythematosus
    LY3009104 (baricitinib, formerly known as JAK1/JAK2 Inhibitor) is a chemical entity that inhibits the activity of the Janus (JAK) 1 and 2 enzymes. LY3009104 is being studied for the treatment of systemic lupus erythematosus.

    For more information on LY3009104 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • Abemaciclib
    LY2835219 (abemaciclib), a chemical entity, is a selective ATP-competitive inhibitor of cyclin dependent kinases (CDK) 4 and 6 that inhibits phosphorylation of the Rb tumor suppressor protein and thereby induces G1 cell cycle arrest. LY2835219 is being studied for the treatment of pancreatic cancer.

    For more information on LY2835219 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • Abemaciclib (a be muh sī klib)
    LY2835219 (abemaciclib), a chemical entity, is a selective ATP-competitive inhibitor of cyclin dependent kinases (CDK) 4 and 6 that inhibits phosphorylation of the Rb tumor suppressor protein and thereby induces G1 cell cycle arrest. LY2835219 is being studied for the treatment of squamous NSCLC.

    For more information on LY2835219 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  

Phase 1

  • BAFF/IL-17 Bispecific Antibody
    "BAFF/IL-17 Bispecific Antibody" is a new biologic entity being studied for the treatment of immune diseases.

     
  • CXCR1/2 Ligands Antibody
    "CXCR1/2 Ligands Antibody" is a new biologic entity being studied for the treatment of immune diseases.

     
  • IL-21 Antibody
    "IL-21 Antibody" is a new biologic entity being studied for the treatment of immune diseases.

     
  • PDE 4 inhibitor
    "PDE4 inhibitor" is a new chemical entity being studied for the treatment of immune diseases.

     
  • Dual Amylin Calcitonin Receptor Agonist
    "DACRA-089" is a new biologic entity being studied for the treatment of diabetes.

     
  • DGAT-2 inhibitor
    "DGAT-2 inhibitor" is a new chemical entity being studied for the treatment of dyslipidemia.

     
  • Insulin-Fc/Dula
    "Basal insulin-Fc + dulaglutide combination" is a new biologic entity being studied for the treatment of diabetes.

     
  • GPR142 agonist
    "GPR142 agonist" is a new chemical entity being studied for the treatment of diabetes.

     
  • hypoglycemia
    New biologic entity.

     
  • Insulin Basal Long Acting
    "Insulin basal long acting" is a new biologic entity being studied for the treatment of diabetes.

     
  • Oxyntomodulin
    "Oxyntomodulin" is a new biologic entity being studied for the treatment of diabetes.

     
  • Aß42 Antibody
    "Aß42 antibody" is a new biologic entity being studied for the treatment of Alzheimer's disease.

     
  • N3pG-Aß Monoclonal Antibody
    "N3pG-Aß Monoclonal Antibody" is a new biologic entity being studied for the treatment of Alzheimer's disease.

     
  • D1 potentiator
    "D1 potentiator" is a new chemical entity being studied for the treatment of dementia.

     
  • Selective BACE 1 inh
    "Selective BACE 1 inhibitor" is a new chemical entity being studied for the treatment of Alzheimer's disease.

     
  • Tau Antibody
    "Tau Antibody" is a new biologic entity being studied for the treatment of Alzheimer's disease.

     
  • Angiopoietin 2 MAb cancer
    "Angiopoietin 2 Antibody" is a new biologic entity being studied for the treatment of cancer.

     
  • CSF-1R Monoclonal Antibody
    "CSF-1R Monoclonal Antibody" is a new biologic entity being studied for the treatment of cancer.

     
  • ERK inhibitor
    "ERK inhibitor" is a new chemical entity being studied for the treatment of cancer.

     
  • PD-L1 Antibody
    "PD-L1 Antibody" is a new biologic entity being studied for development in combination for the treatment of cancer.

     
  • TGFß RI Kinase
    "TGFß Receptor I kinase inhibitor" is a new chemical entity being studied for the treatment of cancer.

     
  • TIM-3 MAb
    "TIM-3 MAb " is a new biologic entity being studied for the treatment of cancer.

     
  • N3pG-Ab Monoclonal Antibody
    "N3pG-Aß Monoclonal Antibody" is a new biologic entity being studied for the treatment of Alzheimer's disease.

     
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Pipeline Disclaimer
The information included on this site reflects Eli Lilly and Company's clinical development pipeline and is not intended for promotional purposes. It includes both new molecular entities as well as select new indications or line extensions of currently-approved products, that are in clinical development. There are significant risks and uncertainties in pharmaceutical research and development. Scientific and regulatory hurdles may cause pipeline molecules to be discontinued, delayed or fail to reach the market. There can be no guarantee that pipeline molecules will receive regulatory approval or that they will prove to be commercially successful. Information is current as of July 21, 2017. Lilly assumes no duty to update this information.

For competitive reasons, some pipeline molecules are not identified; in those instances, only the therapeutic area in which the molecule is being studied is listed.
  • Select NME
  • Select NILEX
  • Diagnostic
GTM-PQNKVL